Michael Friedländer

Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes et al. · JAMA · 2017 · 2.9K citations · Full text

Medicine, Genetics, Oncology +17

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Genome-wide association study identifies novel breast cancer susceptibility loci

Douglas F. Easton, Karen A. Pooley, Alison M. Dunning et al. · Nature · 2007 · 2.3K citations

Life Sciences, Genetics, Molecular Genetics +12

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

Medicine, Gynecology, Oncology +16

Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

David W. Hedley, Michael Friedländer, Ian W. Taylor et al. · Journal of Histochemistry & Cytochemistry · 1983 · 2.1K citations

Medicine, Oncology, Pathology +17